Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
Outlook Therapeutics, Inc. (NASDAQ:OTLK) completed the analysis of the complete 12-week safety and efficacy results for NORSE ...
ophthalmologytimes23h
Outlook Therapeutics completes analysis of 12-week safety and efficacy results of NORSE EIGHT
The trial evaluated ONS-5010 in wet age-related macular degeneration patients, and the company plans to resubmit a Biologics ...
Outlook falls 10% on ONS-5010 update, warrant inducements
Outlook (OTLK) stock fell 10% after the company said it had completed a study analysis for its drug ONS-5010 and entered into ...
Too Old to Operate1d
Association of RPE-BM Complex Thickening with AMD Progression
The following is a summary of “Neuroretinal and RPE changes and susceptibility to Age-Related Macular Degeneration: insights ...
Future Market Insights1d
Retinal Biologics Industry Set to Double USD 41.92 Billion by 2028 at a 11.1% of CAGR
Retinal Biologics Industry. The retinal biologics market experienced significant growth in 2021, with total revenue reaching ...
Ocugen announces first patient dosed in Phase 1 OCU200 trial for DME
Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...
The #1 Nutrient to Protect Your Vision, According to Dietitians
Lutein plays a pivotal role in safeguarding the eyes by filtering blue light, which can penetrate deep into the eye and ...
Outlook Therapeutics’ ONS-5010 shown to be non-inferior to Lucentis in wet AMD
Outlook Therapeutics (OTLK) has completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT, the second of two ...
Regenxbio: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026
Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.
Knowridge1d
How to spot vision loss disease early in older people
The Amsler grid is a simple and effective tool often used to detect early signs of macular degeneration. This is a grid of ...
Both high and low HDL levels are linked to age-related macular degeneration risk
University of California San Diego researchers have identified a U-shaped association between high-density lipoprotein (HDL) ...
Science Daily2d
Genetic risks for age-related macular degeneration
Age-related macular degeneration (AMD), which affects about 200 million people worldwide and can result in legal blindness, impairs an area of the eye (retina) used for reading, driving and many other ...